172 related articles for article (PubMed ID: 25359334)
1. A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation.
Middleton A; Robinson PD; McKay K; Jaffe A; Selvadurai H
Eur Respir J; 2015 Feb; 45(2):541-4. PubMed ID: 25359334
[No Abstract] [Full Text] [Related]
2. Effect of inhaled dry powder mannitol on mucus and its clearance.
Daviskas E; Rubin BK
Expert Rev Respir Med; 2013 Feb; 7(1):65-75. PubMed ID: 23362816
[TBL] [Abstract][Full Text] [Related]
3. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
[TBL] [Abstract][Full Text] [Related]
4. Inhaled mannitol for the treatment of cystic fibrosis.
Hurt K; Bilton D
Expert Rev Respir Med; 2012 Feb; 6(1):19-26. PubMed ID: 22283575
[TBL] [Abstract][Full Text] [Related]
5. Inhaled mannitol and cystic fibrosis. Unnecessary bronchial irritation.
Prescrire Int; 2014 Apr; 23(148):89-91. PubMed ID: 24860889
[TBL] [Abstract][Full Text] [Related]
6. [Dry powder inhalers in cystic fibrosis].
Steinkamp G
Pneumologie; 2014 Jun; 68(6):378-85. PubMed ID: 24664997
[TBL] [Abstract][Full Text] [Related]
7. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.
Bilton D; Robinson P; Cooper P; Gallagher CG; Kolbe J; Fox H; Jaques A; Charlton B;
Eur Respir J; 2011 Nov; 38(5):1071-80. PubMed ID: 21478216
[TBL] [Abstract][Full Text] [Related]
8. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.
Teper A; Jaques A; Charlton B
J Cyst Fibros; 2011 Jan; 10(1):1-8. PubMed ID: 20888307
[TBL] [Abstract][Full Text] [Related]
9. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.
De Boeck K; Haarman E; Hull J; Lands LC; Moeller A; Munck A; Riethmüller J; Tiddens H; Volpi S; Leadbetter J; Charlton B; Malfroot A;
J Cyst Fibros; 2017 May; 16(3):380-387. PubMed ID: 28258928
[TBL] [Abstract][Full Text] [Related]
10. Mannitol dry powder for inhalation: in patients with cystic fibrosis.
Burness CB; Keating GM
Drugs; 2012 Jul; 72(10):1411-21. PubMed ID: 22755516
[TBL] [Abstract][Full Text] [Related]
11. [Inhaled treatments in cystic fibrosis: what's new in 2013?].
Dubus JC; Bassinet L; Chedevergne F; Delaisi B; Desmazes-Dufeu N; Reychler G; Vecellio L;
Rev Mal Respir; 2014 Apr; 31(4):336-46. PubMed ID: 24750953
[TBL] [Abstract][Full Text] [Related]
12. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis.
Minasian C; Wallis C; Metcalfe C; Bush A
Pediatr Pulmonol; 2008 Nov; 43(11):1078-1084. PubMed ID: 18972410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.
Flume PA; Amelina E; Daines CL; Charlton B; Leadbetter J; Guasconi A; Aitken ML
J Cyst Fibros; 2021 Nov; 20(6):1003-1009. PubMed ID: 33715994
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
[TBL] [Abstract][Full Text] [Related]
15. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
[TBL] [Abstract][Full Text] [Related]
16. Question 3: Inhaled mannitol improves lung function in patients with cystic fibrosis.
Winckworth LC; Holme H
Arch Dis Child; 2012 Nov; 97(11):1003-6. PubMed ID: 23100616
[No Abstract] [Full Text] [Related]
17. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Adi H; Young PM; Chan HK; Agus H; Traini D
Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
[TBL] [Abstract][Full Text] [Related]
18. Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.
Hurt K; Bilton D
Respiration; 2014; 88(6):441-8. PubMed ID: 25472021
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
